This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alden, C. Articles by Morton, D. Search for Related Content PubMed PubMed Citation Articles by Alden, C. Articles by Morton, D. Social Bookmarking                   What's this?

Application of Genetically Altered Models as Replacement for the Lifetime Mouse Bioassay in Pharmaceutical Development

Millennium Pharmaceuticals, Cambridge, Massachusetts 02139, alden{at}mpi.com

Peter Smith

Millennium Pharmaceuticals, Cambridge, Massachusetts 02139

Dan Morton

Pharmacia, Skokie, Illinois 60077

The international pharmaceutical regulatory academic and industrial toxicology communities are collaborating to improve the efficiency and effectivenes s of cancer hazard identification based on dramatic improvements in our understanding of the cancer process. Guidelines emanating from the International Conference on Harmonization provide for use of in vivo alternatives. Standard practices utilizing lifetime rat and mouse studies are recognized as seriously flawed with over 80% false positive rates. Furthermore, tobacco, the most important human carcinogen commercialized by industry, is negative in these traditional lifetime studies. The lifetime mouse bioassay is generally recognized in pharmaceutical development as not adding value in safety assessment. An international consortium under the aegis of ILSI has recently completed an evaluation of alternative mouse cancer models. Transgenic models are less expensive, use fewer animals and take less time than traditional lifetime bioassays. These alternative models have now been sufficiently evaluated to be considered useful in the safety assessment plan for pharmaceuticals in development. Specifically for example, the rasH2 appears useful in detecting nongenotoxic as well as genotoxic rodent tumorigens with improved concordance with human response. The p53^+/- heterozygous mouse apparently identifies hormonal carcinogenic mechanisms, immunosuppressive carcinogens, and genotoxic carcinogens. The TG:AC predicts for rodent tumorigens applied topically. Recent experiences at FDA, CPMP, and MHW indicate that with good planning and agency interactions, regulatory acceptability can be anticipated.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Fuhrman, L. Shafer, S. Repertinger, T. Chan, and L. A. Hansen Mechanisms of SEPA 0009-Induced Tumorigenesis in v-rasHa Transgenic Tg.AC Mice Toxicol Pathol, October 1, 2005; 33(6): 623 - 630. [Abstract] [Full Text] [PDF]

				M. M. Elrick, J. A. Kramer, C. L. Alden, E. A. G. Blomme, R. T. Bunch, M. A. Cabonce, S. W. Curtiss, L. D. Kier, K. L. Kolaja, C. P. Rodi, et al. Differential Display in Rat Livers Treated for 13 Weeks with Phenobarbital Implicates a Role for Metabolic and Oxidative Stress in Nongenotoxic Carcinogenicity Toxicol Pathol, January 1, 2005; 33(1): 118 - 126. [Abstract] [Full Text] [PDF]